vs
Avantor, Inc.（AVTR）与RAPID MICRO BIOSYSTEMS, INC.（RPID）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是RAPID MICRO BIOSYSTEMS, INC.的147.5倍（$1.7B vs $11.3M）。Avantor, Inc.净利率更高（3.1% vs -110.8%，领先113.9%）。RAPID MICRO BIOSYSTEMS, INC.同比增速更快（37.3% vs -1.4%）。Avantor, Inc.自由现金流更多（$117.2M vs $-3.3M）。过去两年RAPID MICRO BIOSYSTEMS, INC.的营收复合增速更高（41.8% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
RAPID MICRO BIOSYSTEMS, INC. 是生命科学领域的技术企业，专注于为生物制药厂商、合同研发生产机构等客户提供自动化微生物检测及质控解决方案，可大幅缩短检测周期、提升检测精度，业务覆盖北美、欧洲、亚太等全球核心市场。
AVTR vs RPID — 直观对比
营收规模更大
AVTR
是对方的147.5倍
$11.3M
营收增速更快
RPID
高出38.6%
-1.4%
净利率更高
AVTR
高出113.9%
-110.8%
自由现金流更多
AVTR
多$120.5M
$-3.3M
两年增速更快
RPID
近两年复合增速
-0.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $11.3M |
| 净利润 | $52.4M | $-12.5M |
| 毛利率 | 31.5% | — |
| 营业利润率 | 7.6% | -108.2% |
| 净利率 | 3.1% | -110.8% |
| 营收同比 | -1.4% | 37.3% |
| 净利润同比 | -89.5% | -29.3% |
| 每股收益（稀释后） | $0.08 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRRPID
| Q4 25 | $1.7B | $11.3M | ||
| Q3 25 | $1.6B | $7.8M | ||
| Q2 25 | $1.7B | $7.3M | ||
| Q1 25 | $1.6B | $7.2M | ||
| Q4 24 | $1.7B | $8.2M | ||
| Q3 24 | $1.7B | $7.6M | ||
| Q2 24 | $1.7B | $6.6M | ||
| Q1 24 | $1.7B | $5.6M |
净利润AVTRRPID
| Q4 25 | $52.4M | $-12.5M | ||
| Q3 25 | $-711.8M | $-11.5M | ||
| Q2 25 | $64.7M | $-11.9M | ||
| Q1 25 | $64.5M | $-11.3M | ||
| Q4 24 | $500.4M | $-9.7M | ||
| Q3 24 | $57.8M | $-11.3M | ||
| Q2 24 | $92.9M | $-12.6M | ||
| Q1 24 | $60.4M | $-13.3M |
毛利率AVTRRPID
| Q4 25 | 31.5% | — | ||
| Q3 25 | 32.4% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 33.8% | — | ||
| Q4 24 | 33.4% | — | ||
| Q3 24 | 32.9% | — | ||
| Q2 24 | 34.1% | — | ||
| Q1 24 | 34.0% | — |
营业利润率AVTRRPID
| Q4 25 | 7.6% | -108.2% | ||
| Q3 25 | -40.0% | -145.1% | ||
| Q2 25 | 7.7% | -167.3% | ||
| Q1 25 | 9.3% | -161.8% | ||
| Q4 24 | 37.8% | -124.5% | ||
| Q3 24 | 7.3% | -158.3% | ||
| Q2 24 | 10.3% | -202.1% | ||
| Q1 24 | 8.7% | -254.4% |
净利率AVTRRPID
| Q4 25 | 3.1% | -110.8% | ||
| Q3 25 | -43.8% | -146.8% | ||
| Q2 25 | 3.8% | -163.3% | ||
| Q1 25 | 4.1% | -156.3% | ||
| Q4 24 | 29.7% | -117.6% | ||
| Q3 24 | 3.4% | -148.9% | ||
| Q2 24 | 5.5% | -190.1% | ||
| Q1 24 | 3.6% | -237.4% |
每股收益（稀释后）AVTRRPID
| Q4 25 | $0.08 | $-0.26 | ||
| Q3 25 | $-1.04 | $-0.26 | ||
| Q2 25 | $0.09 | $-0.27 | ||
| Q1 25 | $0.09 | $-0.26 | ||
| Q4 24 | $0.73 | $-0.22 | ||
| Q3 24 | $0.08 | $-0.26 | ||
| Q2 24 | $0.14 | $-0.29 | ||
| Q1 24 | $0.09 | $-0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $20.0M |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | $33.2M |
| 总资产 | $11.8B | $74.9M |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTRRPID
| Q4 25 | $365.4M | $20.0M | ||
| Q3 25 | $251.9M | $18.9M | ||
| Q2 25 | $449.4M | $18.3M | ||
| Q1 25 | $315.7M | $18.9M | ||
| Q4 24 | $261.9M | $16.9M | ||
| Q3 24 | $285.3M | $22.0M | ||
| Q2 24 | $272.6M | $37.1M | ||
| Q1 24 | $234.9M | $22.4M |
总债务AVTRRPID
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTRRPID
| Q4 25 | $5.6B | $33.2M | ||
| Q3 25 | $5.6B | $44.3M | ||
| Q2 25 | $6.3B | $54.5M | ||
| Q1 25 | $6.1B | $65.5M | ||
| Q4 24 | $6.0B | $75.4M | ||
| Q3 24 | $5.6B | $84.4M | ||
| Q2 24 | $5.4B | $94.6M | ||
| Q1 24 | $5.3B | $105.9M |
总资产AVTRRPID
| Q4 25 | $11.8B | $74.9M | ||
| Q3 25 | $11.7B | $84.4M | ||
| Q2 25 | $12.8B | $75.6M | ||
| Q1 25 | $12.3B | $85.4M | ||
| Q4 24 | $12.1B | $98.2M | ||
| Q3 24 | $12.8B | $105.8M | ||
| Q2 24 | $12.7B | $117.1M | ||
| Q1 24 | $12.8B | $127.7M |
负债/权益比AVTRRPID
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $-3.2M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $-3.3M |
| 自由现金流率自由现金流/营收 | 7.0% | -29.6% |
| 资本支出强度资本支出/营收 | 2.1% | 0.8% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | $-31.9M |
8季度趋势，按日历期对齐
经营现金流AVTRRPID
| Q4 25 | $152.7M | $-3.2M | ||
| Q3 25 | $207.4M | $-9.1M | ||
| Q2 25 | $154.4M | $-9.7M | ||
| Q1 25 | $109.3M | $-9.1M | ||
| Q4 24 | $173.3M | $-9.9M | ||
| Q3 24 | $244.8M | $-8.6M | ||
| Q2 24 | $281.1M | $-10.1M | ||
| Q1 24 | $141.6M | $-15.5M |
自由现金流AVTRRPID
| Q4 25 | $117.2M | $-3.3M | ||
| Q3 25 | $171.7M | $-9.1M | ||
| Q2 25 | $124.8M | $-10.1M | ||
| Q1 25 | $81.3M | $-9.4M | ||
| Q4 24 | $145.8M | $-10.0M | ||
| Q3 24 | $204.0M | $-8.8M | ||
| Q2 24 | $235.3M | $-10.6M | ||
| Q1 24 | $106.9M | $-16.1M |
自由现金流率AVTRRPID
| Q4 25 | 7.0% | -29.6% | ||
| Q3 25 | 10.6% | -116.4% | ||
| Q2 25 | 7.4% | -138.6% | ||
| Q1 25 | 5.1% | -130.2% | ||
| Q4 24 | 8.6% | -121.8% | ||
| Q3 24 | 11.9% | -116.0% | ||
| Q2 24 | 13.8% | -159.8% | ||
| Q1 24 | 6.4% | -287.1% |
资本支出强度AVTRRPID
| Q4 25 | 2.1% | 0.8% | ||
| Q3 25 | 2.2% | 0.9% | ||
| Q2 25 | 1.8% | 5.0% | ||
| Q1 25 | 1.8% | 4.4% | ||
| Q4 24 | 1.6% | 1.2% | ||
| Q3 24 | 2.4% | 2.9% | ||
| Q2 24 | 2.7% | 6.9% | ||
| Q1 24 | 2.1% | 10.4% |
现金转化率AVTRRPID
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
RPID
| Products | $9.3M | 83% |
| Services | $2.0M | 17% |
